However, here, as in other advanced cancer settings, plasma scMet was a marker of poor prognosis, while tumor cMet, HGF and cMet–HGF trended in the same direction, suggesting that these measures may be inadequate to predict benefit from dual pathway inhibition, or that this Phase I dose-finding study was underpowered to detect the impact of these prognostic markers. Here, MET is linked to cancer.